SEOUL – November 04, 2026 -- Hugel Inc. reported third-quarter net sales of KRW97.5 billion, with operating profit of KRW18.1 billion and net profit of KRW4.7 billion, as the South Korean aesthetics group absorbed a short-term hit from restructuring its U.S. sales model. Consolidated net sales for the first three quarters of 2026 totaled KRW352.1 billion, up 15% year-on-year.

Botulinum toxin sales fall 21% while fillers and cosmetics grow

Botulinum toxin net sales, domestic and international combined, came in at KRW47.2 billion in the third quarter, down 21% year-on-year. Hyaluronic acid (HA) dermal fillers and skinboosters rose 2% to KRW30.9 billion. Cosmetics and other businesses reached KRW19.4 billion, growing more than 25%.

Korea combined sales jump 54% to KRW27.4 billion

Combined net sales of botulinum toxin, HA fillers and skinboosters in Korea rose 54% year-on-year to KRW27.4 billion. The combined figure has increased quarter-on-quarter every quarter since the third quarter of 2025.

Europe grows 18% as Hugel holds 22% of China's toxin market

In Europe and other regions, combined sales of the three categories rose 18% year-on-year to KRW17.8 billion. In China, Hugel holds the second-highest botulinum toxin market position with a 22% share. In Brazil, the company posted record quarterly sales and market share, coinciding with the first anniversary of its market re-entry.

U.S. distributor deal converts to contract sales organization

In the U.S., Hugel converted its distributor partnership into a contract sales organization (CSO) model. The company says the change brings strategic benefits despite a short-term impact on results, and it reports early growth momentum.

Global CEO Carrie Strom said Hugel will use its botulinum toxin Letybo to strengthen mid- to long-term profitability in the U.S., which she called the company's core market. Korea CEO Daniel Chang said Hugel plans to strengthen its core businesses while expanding and diversifying its product portfolio.